210536-90-6Relevant articles and documents
ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
-
Page/Page column 167; 168, (2021/09/17)
Provided herein are novel compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.
Highly reactive, general, and long-lived catalysts for coupling heteroaryl and aryl chlorides with primary nitrogen nucleophiles
Shen, Qilong,Shekhar, Shashank,Stambuli, James P.,Hartwig, John F.
, p. 1371 - 1375 (2007/10/03)
Resisting pathways for decomposition followed by palladium complexes of monodentate ligands is one characteristic of the highly reactive but long-lived catalyst generated from the Josiphos ligand L and palladium. It catalyzes under mild conditions the coupling of primary amines with chloropyridines and chloroarenes in high yield with low catalyst loadings (see scheme).
A palladium-catalyzed strategy for the preparation of indoles: A novel entry into the Fischer indole synthesis
Wagaw,Yang,Buchwald
, p. 6621 - 6622 (2007/10/03)
-
